California Public Employees Retirement System continued to hold its stake in shares of SCYNEXIS, Inc. (NASDAQ:SCYX) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 200,000 shares of the company’s stock at the end of the second quarter. California Public Employees Retirement System owned approximately 0.78% of SCYNEXIS worth $358,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Federated Investors Inc. PA boosted its stake in SCYNEXIS by 23.5% during the second quarter. Federated Investors Inc. PA now owns 4,208,400 shares of the company’s stock valued at $7,533,000 after buying an additional 800,040 shares in the last quarter. Vanguard Group Inc. boosted its stake in SCYNEXIS by 6.0% during the second quarter. Vanguard Group Inc. now owns 868,394 shares of the company’s stock valued at $1,554,000 after buying an additional 48,978 shares in the last quarter. GSA Capital Partners LLP boosted its stake in SCYNEXIS by 33.7% during the second quarter. GSA Capital Partners LLP now owns 176,700 shares of the company’s stock valued at $316,000 after buying an additional 44,500 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in SCYNEXIS by 1.4% during the first quarter. Bank of New York Mellon Corp now owns 37,523 shares of the company’s stock valued at $103,000 after buying an additional 512 shares in the last quarter. 30.45% of the stock is owned by institutional investors and hedge funds.

SCYNEXIS, Inc. (NASDAQ SCYX) opened at $1.88 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 7.30 and a current ratio of 7.30. SCYNEXIS, Inc. has a 1 year low of $1.52 and a 1 year high of $4.04.

Several brokerages recently weighed in on SCYX. Zacks Investment Research cut SCYNEXIS from a “buy” rating to a “hold” rating in a research note on Wednesday, September 6th. ValuEngine cut SCYNEXIS from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 22nd. Guggenheim began coverage on SCYNEXIS in a research note on Tuesday, October 24th. They set a “buy” rating and a $6.00 target price for the company. HC Wainwright set a $14.00 target price on SCYNEXIS and gave the company a “buy” rating in a research note on Wednesday, August 16th. Finally, Roth Capital set a $9.00 target price on SCYNEXIS and gave the company a “buy” rating in a research note on Monday, August 7th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. SCYNEXIS has a consensus rating of “Buy” and an average price target of $8.43.

COPYRIGHT VIOLATION NOTICE: This piece was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/scynexis-inc-scyx-position-held-by-california-public-employees-retirement-system/1727048.html.

SCYNEXIS Company Profile

SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.

Institutional Ownership by Quarter for SCYNEXIS (NASDAQ:SCYX)

Receive News & Ratings for SCYNEXIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.